Last reviewed · How we verify

NCT05758909: FAST TRACK

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

Active, enrolled Last updated 19 December 2025
What this trial tests

trial testing TF TAVI in Aortic Valve Disease in 585 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 April 2023
Primary endpoint
1 December 2026
1 December 2026

Quick facts

Lead sponsorFundación EPIC
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment585
Start date4 April 2023
Primary completion1 December 2026
Estimated completion1 December 2026
Sites13 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundación EPIC — full company profile →

Who can join

18 and older, any sex, with Aortic Valve Disease or Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Valve Disease

Currently open trials in the same condition.

Other Fundación EPIC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05758909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing